Earlier quoted context omitted.
Yes, however, the "drug" described (it's more of an idea for a drug at this stage, really) does not aim to disrupt the tumor cell itself. Instead it's based on the observation that many (maybe most?) cancerous cells over-express the protein CD47 on their surfaces as a survival mechanism in order to prevent macrophages and dendrites from taking them out. If successful - and that's a big if, because I'd be willing to w…
Unfortunately, evolution is evolution, and if there is any way that cancer cells can trick the immune system that does not require CD47, trust me we'll know about it after the first few months using this drug. We've probably learned more about the intricate inner workings of cells by studying the ways in which cancers can evade treatments than by any other method. Still, I don't doubt this will be another tool in the…
Unfortunately, evolution is evolution, and if there is any way that
cancer cells can trick the immune system that does not require CD47,
trust me we'll know about it after the first few months using this drug.
I totally agree. Also, I'm skeptical about side effects. We'll see. As I said, I don't believe this will come out as an actual drug. What I find mildly disappointing is that cancer is an evolutionary
process, but it is still treated primarily as a cell signaling disease.
Absolutely. We spend a lot of time figuring out the biochemical intricacies of very specialized tumor cells with, predictably, not a lot to show for it. My guess is we'll be making inroads this way as far as pre-cancerous and early stage disease is concerned but we simply lack the technology to deal with the phenomenon itself. To speculate further, I don't think this will be solved by micro-advancements in pharmaceuticals (even quite well-targeted ones), I believe we need a new class of active agent that can go in there and make decisions on a cell-by-cell basis if necessary.